Humira patent thicket number of patents?

Humira (adalimumab) sits at the center of a “patent thicket” that’s been described as comprising roughly 70‑80 active patents in the United States. Those claims cover everything from the drug’s amino‑acid sequence and formulation to methods of use, delivery devices, and manufacturing processes.

The exact number can fluctuate—patents expire, new ones are filed, and some claims may be invalidated or abandoned—so the figure you’ll see in the USPTO or the FDA’s “patents for Humira” docket usually falls in that range. If you need a precise, up‑to‑date count, the USPTO’s PATFT database or the FDA’s “Biologic License Application” docket for Humira will list all active claims at any given time.